A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease

References

• Cancer Stats: Leukemia–acute lymphoblastic leukemia (ALL) [Internet]. Bethesda (MD): NIH-NCI. NIH-National Cancer Institute–acute lymphoblastuc leukenia (ALL); 2019 [cited 2019 December 13]. Available from: https://seer.cancer.gov/statfacts/html/alyl.html.
   Google Scholar
• Pulte D, Jansen L, Gondos A, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PloS One. 2014;9(1):e85554.
   PubMed Web of Science ®Google Scholar
• Fielding A, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
   PubMed Web of Science ®Google Scholar
• Rowe J, Buck G, Burnett A, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–1876.
   PubMed Web of Science ®Google Scholar
• Hoelzer D. Personalized medicine in adult acute lymphoblastic leukemia. Haematologica. 2015;100(7):855–858.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Pigneux A, Montesinos P, Cong Z, et al. Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. BMC Cancer. 2018;18(1):1100–1109.
   PubMedGoogle Scholar
• Bar M, Wood B, Radich J, et al. Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. Leuk Res Treatment. 2014;2014:1–9.
   Google Scholar
• Sanchez-Garcia J, Serrano J, Serrano-Lopez J, et al. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL. Bone Marrow Transpl. 2013;48(3):396–402.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612–618.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4(7):e225.
   PubMedGoogle Scholar
• NCCN. NCCN Clinical Practice Guidelines in Oncology - Acute Lymphoblastic Leukemia (Version 5.2017 - October, 2017) 2017. [cited 2020 Jan 9]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
   Google Scholar
• Appelbaum F. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res: Clin Haematol. 2013;26(3):279–284.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162.
   PubMed Web of Science ®Google Scholar
• Cai WZ, Cen JN, Chen J, et al. Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission. Bone Marrow Transpl. 2017;52(3):470–472.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Potter M, et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: an analysis by the Acute Leukemia Working Party of the EBMT. Euro J Cancer. 2018;96:73–81.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Braggemann M, Beck J, et al. Evaluation of minimal residual disease (MRD) and MRD-based treatment decisions in Ph/BCR-ABL negative adult acute lymphoblastic leukemia (ALL): experience from the German Multicenter Study Group for Adult ALL (GMALL). Blood. 2017;130(1):139.
   Google Scholar
• Kunter G, Perkins JB, Pidala J, et al. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transpl. 2014;49(1):11–16.
   PubMed Web of Science ®Google Scholar
• Lussana F, Intermesoli T, Gianni F, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transpl. 2016;22(11):1983–1987.
   PubMed Web of Science ®Google Scholar
• Zhang M, Fu H, Lai X, et al. Minimal residual disease at first achievement of complete remission predicts outcome in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. PLoS One. 2016;11(10):1–11.
   Web of Science ®Google Scholar
• Bachanova V, Marks D, Zhang M, et al. Ph + ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia. 2014;28(3):658–665.
   PubMed Web of Science ®Google Scholar
• Mannis G, Martin T, Damon L, et al. Quantification of acute lymphoblastic leukemia clonotypes in leukapheresed peripheral blood progenitor cells predicts relapse risk after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(6):1030–1036.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Socié G, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(1):139–149.
   PubMed Web of Science ®Google Scholar
• Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transpl. 2010;45(6):1095–1101.
   PubMed Web of Science ®Google Scholar
• Helbig G, Krawczyk-Kulis M, Kopera M, et al. Autologous hematopoietic stem cell transplantation for high-risk acute lymphoblastic leukemia: non-randomized study with a maximum follow-up of more than 22 years. Mediterr J Hematol Infect Dis. 2014;6(1):e2014047.
   PubMedGoogle Scholar
• Cerrada SL, Marin D, Rondon G. Impact of new anti-leukemia agents on transplant outcomes in adults with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic cell transplantation (HCT) in second complete remission. Blood. 2016;128(22):4676–4676.
   Google Scholar
• Huang A, Huang C, Tang G, et al. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia. Leukemia and Lymphoma. 2018;59(5):1073–1083.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short N, Jorgensen J, et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017;123(2):294–302.
   PubMed Web of Science ®Google Scholar
• Logan A, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transpl. 2014;20(9):1307–1313.
   PubMed Web of Science ®Google Scholar
• Short N, Kantarjian H, Jorgensen J, et al. Achievement of minimal residual disease negativity by multiparameter flow cytometry is an important therapeutic endpoint in patients with relapsed/refractory B-cell acute lymphoblastic leukemia receiving salvage treatment. Blood. 2016;128(22):2916–2916.
   Web of Science ®Google Scholar
• Zhou Y, Slack R, Jorgensen J, et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymph, Myeloma & Leukemia. 2014;14(4):319–326.
   PubMed Web of Science ®Google Scholar
• Lozenov S, Spassov B, Petrov Y, et al. Comparison of the prognostic significance of minimal residual disease and the conventional prognostic factors in the treatment of adult acute lymphoblastic leukaemia patients. Abstract PB 1608, Presented at 21st European Hematology Association congress, Copenhagen, 2016.
   Google Scholar
• Saygin C, Papadantonakis N, Cassaday R, et al. Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response [Article. Leukemia and Lymphoma. 2018;59(2):363–371.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Bassett R, Lyons G, et al. Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results. Biolo Blood and Marrow Transpl. 2017;23(2):285–292.
   PubMed Web of Science ®Google Scholar
• Kanakry C, Tsai H, Bolanos-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124(25):3817–3827.
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu Y, Qin Y, et al. Pre-transplant minimal residual disease determined by multiparameter flow cytometry is better than RQ-PCR to predict the outcomes of PH + ALL patients receiving allogeneic hematopoietic stem cell transplantation. Blood. 2017;130(1):1998.
   Google Scholar
• Tucunduva L, Ruggeri A, Sanz G, et al. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2014;166(5):749–757.
   PubMed Web of Science ®Google Scholar
• Kim M, Park J, Kim D, et al. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone Marrow Transplant. 2015;50(3):354–362.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1(25):2456–2466.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Gokbuget N, Kantarjian HM, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019;125(23):4181–4192.
   PubMed Web of Science ®Google Scholar